NICE - National Institute for Health and Care Excellence

NICE Guidance: Asciminib for treating myeloid leukemia after 2 or more tyrosine kinase inhibitors
Published August 2022

Click here to view the full guidance

Click 'Read more'  to find more NICE guidances

NICE Guidance: Ponatinib for treating chronic myeloid leukemia and acute lymphoblastic leukemia
Published June 2017
Click here to view the full guidance

NICE Guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib
Published December 2016
Click here to veiw the full guidance

NICE Guidance: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukemia
Published December 2016
Click here to see the full guidance

NICE Guidance: Bosutinib for previously treated chronic myeloid leukemia
Published August 2016
Click here to see the full guidance

NICE Guidance on the use of imatinib for chronic myeloid leukaemia
Published October 2003; last modified January 2016
Click here to view the full guidance